Gain of Glutaminase Function in Mutants of the Ammonia-specific Frog Carbamoyl Phosphate Synthetase*

Amna Saeed-Kothe and Susan G. Powers-Lee {ddagger}

From the Department of Biology, Northeastern University, Boston, Massachussetts 02115

Received for publication, April 10, 2003 , and in revised form, May 7, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Depending on their physiological role, carbamoyl phosphate synthetases (CPSs) use either glutamine or free ammonia as the nitrogen donor for carbamoyl phosphate synthesis. Sequence analysis of known CPSs indicates that, regardless of whether they are ammonia- or glutamine-specific, all CPSs contain the structural equivalent of a triad-type glutamine amidotransferase (GAT) domain. In ammonia-specific CPSs, such as those of rat or human, the catalytic inactivity of the GAT domain can be rationalized by the substitution of the Triad cysteine residue by serine (1). The ammonia-specific CPS of Rana catesbeiana (fCPS) presents an interesting anomaly in that, despite its retention of the entire catalytic triad (2) and almost all other residues conserved in Triad GATs, it is unable to utilize glutamine as a nitrogen-donating substrate (3). Based on our earlier work with the glutamine-utilizing E. coli CPS (eCPS), we have targeted residues Lys258 and Glu261 in the fCPS GAT domain as critical for preventing GAT function. Previously we have shown that substitution of the corresponding residues in eCPS by their fCPS counterparts (Leu -> Lys and Gln -> Glu) resulted in complete loss of GAT function in eCPS (3). To examine the role of these residues in the fCPS GAT component, we have cloned the full-length fCPS gene from R. catesbeiana liver. Here we report the first heterologous expression of an ammonia-specific CPS and show that a single mutation of the frog enzyme, K258L, yields a gain of glutaminase function.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
The evolution of a urea cycle that effectively removes excess, potentially neurotoxic ammonia was critical for the adaptation of life to a terrestrial rather than aquatic habitat (46). Arginine biosynthetic pathways were most likely the evolutionary precursors of the urea cycle, with very few changes needed for pathway transformation (6). Four of these changes occurred in the enzyme that catalyzes the entry and rate-limiting step of the urea cycle, carbamoyl phosphate synthetase (CPS),1 and they were as follows: (i) a decrease in Km for ammonia to ~1 from ~100 mM; (ii) a loss of interaction with glutamine to avoid competition with the preferred substrate ammonia; (iii) localization to the hepatic mitochondrial matrix to allow independent regulation and avoid futile cycling; and (iv) gain of communication with a sensor of excess amino acids, N-acetyl-glutamate (AGA, which serves as an essential allosteric activator only for urea-synthesizing CPSs). In addition to the ammonia-specific CPS required for urea synthesis, most organisms also express a cytosolic glutamine-specific CPS that is involved in pyrimidine biosynthesis. In Escherichia coli, a single, glutamine-specific CPS (eCPS) participates in both arginine and pyrimidine synthetic pathways.

Glutamine-utilizing CPSs, e.g. eCPS, bind and cleave glutamine at a glutamine amidotransferase (GAT) domain and channel the resulting free ammonia, sequestered within the enzyme, to a synthetase (SYN) domain where all other ligands are bound and all other reactions take place (7, 8). Ammonia can substitute for glutamine in eCPS, but with a much higher Km (111 versus 0.17 mM; Ref. 3). The contrasting properties of ammonia-specific CPSs are even more intriguing when considered in the broader context of the GAT family (comprising the Triad and Ntn subfamilies) that participates in biosynthetic pathways for amino acids, amino sugars, coenzymes, and purine and pyrimidine nucleotides (9). Of the hundreds of GAT family members characterized in various organisms and tissues, these CPSs are the only enzymes that share the family-defining sequence motifs but have lost the ability to utilize glutamine and gained the ability to scavenge low levels of ammonia. For rat and human ammonia-specific CPSs, loss of glutamine usage is explained, at least in part, by substitution of serine for the cysteine of the catalytic triad (1, 10). However, the ammonia-specific CPS of Rana catesbeiana (fCPS) retains the entire catalytic triad (2) and almost all of the other amino acids conserved in Triad GATs (3) and, thus, is an ideal candidate for detailed elucidation of the molecular basis for glutamine discrimination in CPSs. Here we report that the present day frog ammonia-specific CPS retains an unexpectedly close link to glutamine-utilizing CPSs, with only a single mutation required for gain of glutaminase function.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Strains, Plasmids, and Recombinant DNA Methods—The ESP® yeast protein expression and purification system, including the Schizosaccharomyces pombe host strain SP-Q01 and Edinburgh minimal medium, was from Stratagene. The S. pombe expression plasmid pESP-5 (11) was the generous gift of Quinn Lu (GlaxoSmithKline). pCR2.1, used for cloning of PCR products, was from Invitrogen. S. pombe transformations were carried out according to the supplier (Stratagene). QuikChangeTM was used for site-directed mutagenesis (Stratagene), and fidelity was verified by sequencing. Mutagenesis primers (mutated codons set in boldface) were as follows for K258L, E261Q, and K258L/E261Q, respectively: 5'-TTTGGCATCTGTCTCGGGAATGAAATTGCAGCTTTGGC-3'; 5'-TTTGGCATCTGTAAAGGGAATCAAATTGCAGCTTTGGC-3'; and 5'-TTTGGCATCTGTCTCGGGAATCAAATTGCAGCTTTGCC-3'.

Cloning of Full-length fCPS cDNA—R. catesbeiana total RNA was prepared from frozen liver with the SV total RNA isolation system (Promega) for amplification of full-length fCPS in reverse transcription PCR reactions (RNA LA PCR Kit, Version 1.1; Takara Bio Inc.) with the supplied oligo(dT)-adaptor primer and the gene-specific primer pair, respectively, as follows: 5'-TTCGGCATATGAGCGTCAAGGC-3' (NdeI site and start codon underlined); and 5'-ATAGTTCAGATCCCTAGGAGGG-3' (AvrII site and stop codon set in boldface). The 4.4-kb fCPS amplicon was cloned into pCR2.1 (3.9 kb) to yield fCPS-pCR2.1, and the sequence of the entire gene was verified on both strands. This cDNA encodes the mature fCPS protein (1463 amino acids) with a methionine replacing the 33 N-terminal residues comprising the mitochondrial matrix-targeting sequence. An NheI site (underlined) was introduced at the 5'-end of the fCPS gene to allow subcloning an NheI-BamHI fragment into pESP-5 (11), with 5'-TAAGAAGGAGCTAGCCATATGAGCGTCAAGGC-3' as the mutagenic primer. The final expression construct encoded the mature fCPS protein fused to an N-terminal His6-FLAG® tag (HHHHHHDYKDDDKHASHM).

Purification of CPS—Native frog liver (12) and recombinant E. coli CPSs (3) were prepared as described previously. Recombinant wild type and mutant fCPS proteins were expressed in S. pombe following an 18–22-h induction in 1-liter Edinburgh minimal medium according to the supplier's protocol (Stratagene). Cells were harvested, resuspended in 10–12 ml of Buffer A (5 mM imidazole, 0.5 M NaCl, and 20 mM Tris, pH 7, 4 °C) containing 2 mM phenylmethylsulfonyl fluoride and 0.1 mM each pepstatin, antipain, leupeptin, chymostatin, and aprotinin, and transferred to a 50-ml BioSpec bead beater chamber half-filled with pre-wetted, chilled glass beads (0.5-mm diameter). The chamber was completely filled with glass beads, sealed, and immersed in an ice, salt, and water slurry. Cells were lysed by bead beating in 1-min pulses for a total of 3–5 pulses. The homogenate was rinsed out of the chamber with Buffer A (plus protease inhibitors) in a total volume of 50 ml and clarified by centrifugation, followed by passage through a 0.450-µm Millex-HA (Millipore) filter. Cleared lysate ({approx}50 ml) was applied to a Hi-TrapTM chelating HP 5-ml column (ÄKTA FPLC, Amersham Biosciences) charged with 0.5 M NiSO4 and equilibrated in Buffer A. Bound protein was eluted from the column with a 0–40% discontinuous gradient (0–10% in 25 ml, 10–40% in 100 ml) of 0.5 M imidazole in Buffer A. The fCPS-containing fractions, eluting at 100–150 mM imidazole, were pooled and concentrated by the addition of solid ammonium sulfate to 90%. The protein was resuspended in 5–10 ml of Buffer B (10 mM Tris, 5 mM MgCl2, 1 mM dithiothreitol, and 1 mM EDTA, pH 8.1), and loaded on a Hi-PrepTM 26/60 Sephacryl 200 column. fCPS was eluted from this column in Buffer B, concentrated in Centriplus YM100 centrifugal filter devices to >5 mg/ml, and stored frozen at –80 °C. SDS-PAGE analysis indicated >= BORDER="0"> 95% purity for all constructions. Because protease treatments necessary to remove fusion partners also result in proteolysis of fCPS, presumably at the links between domains (1316), in the present studies we retained the tag in all fCPS constructions.

Enzyme Assays and Data Analysis—CP synthesis was measured by coupling the CPS reaction to that of ornithine transcarbamoylase and quantitating the resulting citrulline (3, 17). Glutamine-dependent and ammonia-dependent ADP formations were determined in a pyruvate kinase/lactate dehydrogenase-coupled assay as described previously (3, 17). To determine ammonium-dependent ADP formation, 30 mM NH4Cl was included in the reaction mixture; to determine glutamine-dependent ADP formation, 10 mM glutamine was included. Although only the unprotonated form of ammonia is a substrate for CPSs (18, 19), the data are presented as the total of [NH4+] + [NH3] because it is the level of NH4Cl that is varied during the experiments. Under the conditions of the present studies, NH3 represents about 4% of the total NH4+ added to the solution (18). Glutamine hydrolysis was determined by coupling glutamate formation to the glutamate dehydrogenase-catalyzed reduction of 3-acetyl pyridine dinucleotide (3). Kinetic data were fit by non-linear regression (GraFit, version 5.1) to the equation {nu} = VmaxS/(Km + S), where {nu} is the initial velocity, Vmax is the maximal velocity, S is the substrate concentration, and Km is the Michaelis-Menten constant. Binding of glutamine to CPSs was determined in a radiometric assay as described previously (3).


    RESULTS AND DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Cloning, Expression, and Characterization of Wild Type fCPS—Despite the critical role of ammonia-specific liver CPS, this enzyme has not been as extensively studied as the glutamine-dependent CPSs, primarily due to the absence of a recombinant expression system. Previously, our laboratory has tried unsuccessfully to express ammonia-dependent CPSs in several bacterial expression systems, with inclusion bodies resulting in all cases. However, we have been able to express fCPS as a soluble, active protein from the expression vector pESP-5 (11) in the fission yeast S. pombe. Full-length fCPS was cloned from R. catesbeiana liver and inserted in pESP-5 as described under "Experimental Procedures." fCPS was expressed as the mature protein (1463 amino acid residues), with the 33 N-terminal residues of the fCPS precursor replaced by a methionine (set in boldface) and the His6-FLAG® fusion tag (HHHHHHDYKDDDKHASHM). The N-terminal residues that were replaced serve as a mitochondrial matrix-targeting signal and are normally cleaved as the fCPS precursor crosses the inner mitochondrial membrane (2). A two-step purification protocol, with nickel affinity and size exclusion chromatography, yielded 10–15 mg of pure soluble fCPS per liter of yeast culture medium. Because our previous attempts to remove fusion partners by protease treatment revealed additional proteolysis sites in fCPS, presumably at the links between domains that are extremely susceptible to proteolysis (1316), we retained the tag in all fCPS constructions.

The kinetic and physical properties of recombinant wild type fCPS were very similar to those observed for the native frog enzyme, indicating that the structure of the recombinant protein mirrors that of the native protein and further indicating that the fusion tag is a functionally neutral modification. Recombinant and native fCPSs exhibited comparable ammonia-dependent CP synthesis activities (1.17 and 1.12 µmol CP/min/mg, respectively), similar kcat and Km values for ammonia and ATP (Table I), and both required the presence of the essential allosteric activator, AGA. SDS-PAGE analysis confirmed that recombinant fCPS was the expected size (162 kDa), and recombinant and native fCPSs yielded essentially identical gel filtration profiles (data not shown).


View this table:
[in this window]
[in a new window]
 
TABLE I
Kinetic Parameters for Utilization of Ammonia and ATP by fCPSs

 

Gain of Glutaminase Function in fCPS Mutants—Based on analysis of GAT residues that are conserved in glutamine-utilizing CPSs but not ammonia-specific CPSs (Fig. 1), we have identified Lys258 and Glu261 as residues critical for preventing glutamine usage by fCPS (3). Additional rationale for targeting these residues was provided by our previous demonstration that simultaneous occurrence of the corresponding substitutions in eCPS (Leu -> Lys and Gln -> Glu) prevent it from using glutamine (3). Here we have constructed in fCPS the reverse mutants K258L, E261Q, and K258L/E261Q. Both K258L and K258L/E261Q could synthesize CP in the presence of glutamine, whereas E261Q could not (Fig. 2). K258L, K258L/E261Q, fCPS, and eCPS had similar rates for ammonia-dependent CP synthesis (1.05–1.17 µmol/min/mg), whereas E261Q functioned at about 60% of this rate. AGA was required for CP synthesis by all fCPS constructs, with either glutamine or ammonia as the nitrogen source. The absence of a solved structure for fCPS prevents detailed structure/function analysis of the mutants. However, our findings clearly demonstrate that the presence of lysine at position 258 precluded use of glutamine and confirmed the critical role of leucine at this position.



View larger version (13K):
[in this window]
[in a new window]
 
FIG. 1.
Comparison of invariant residues in the GAT domains of glutamine-utilizing and ammonia-specific CPSs. Amino acid sequence alignment (Munich Information Center for Protein Sequences) of 23 different glutamine-utilizing CPSs, represented by eCPS, revealed 29 residues that are invariant. Of these, 25 are also invariant in ammonia-specific CPSs, including fCPS (R. catesbeiana), rCPS (Rattus norvegicus), and hCPS (Homo sapiens). Lys258 of fCPS, though not invariant, was included because its polar character is very distinct from the nonpolar Leu or Met residues found at this position in all glutamine-utilizing CPSs. The Cys-His-Glu catalytic triad ({downarrow}) and the nine invariant residues (boldface) found in all Triad GAT domains (9) are also indicated.

 


View larger version (26K):
[in this window]
[in a new window]
 
FIG. 2.
Glutamine- and ammonia-dependent CP synthesis by fCPSs. Rates of ammonia-dependent (gray bars) and glutamine-dependent (hatched bars) CP synthesis were determined for native, recombinant, and K258L, E261Q, and K258L/E261Q fCPSs in the presence of 30 mM NH4Cl or 10 mM glutamine as described previously (3). Comparison data for eCPS (3) are included.

 

To further define the interaction of the mutants with glutamine, we directly measured glutamine hydrolysis (Table II). Like other members of the GAT family, eCPS can catalyze glutamine hydrolysis in the absence of additional substrates (7), although the rate of this uncoupled partial reaction is extremely slow (kcat 0.24 min1; Ref. 20). This activity increases dramatically (kcat 1.5 s1; Table II) when glutamine hydrolysis is coupled to CP synthesis on the SYN domain (7) by the addition of ATP and bicarbonate. Neither fCPS nor E261Q exhibited detectable hydrolysis or even binding of glutamine under any of the conditions tested. When saturating amounts of ATP and bicarbonate were present, both K258L and K258L/E261Q had robust glutaminase activities (Table II), although the kcat values were 7.5-fold lower than that of eCPS. It should be noted that the eCPS glutaminase kcat value of 1.5 s1 was lower than the value of 3.4–4.7 s1 predicted by the ADP formation kcat values (6.8 and 9.4 s1; Table II). Presumably, these kcat differences reflect the different coupling systems used in the assays. The double mutant exhibited a Km for glutamine that was about equal to that of eCPS (0.20 versus 0.15 mM), whereas K258L had a 23-fold elevated Km for glutamine (3.45 mM), indicating that the E261Q mutation facilitated interaction with glutamine. Surprisingly, given the well established effect on eCPS behavior (7, 20), elimination of coupling with CP synthesis had no effect on the glutaminase activity of K258L and K258L/E261Q. When ATP was omitted from the glutaminase mix, kcat values remained unchanged (0.2 s1 for both mutants), and the Km values showed little change (6.57 mM for K258L and 0.74 mM for K258L/E261Q). This lack of response to SYN substrates suggested that the fCPS mutants did not communicate occupancy of the SYN active site to the GAT active site but, rather, had GAT active sites that were permanently in the high activity conformation. It is also note-worthy that, for both K258L and K258L/E261Q, AGA had no effect on glutaminase activity.


View this table:
[in this window]
[in a new window]
 
TABLE II
Kinetic Parameters for Utilization of Glutamine and ATP by fCPSs

 

Ability of fCPS Mutants to Synchronize Catalysis at the Multiple Active Sites—Next, we assessed the effects of the GAT mutants on SYN domain function via ADP formation assays. Formation of the high energy intermediate CP requires concomitant cleavage of two molecules of ATP to form two ADPs (19, 21). In ammonia-dependent ADP formation assays, K258L and K258L/E261Q displayed wild type kinetic parameters for ammonia and ATP usage (Table I). The E261Q mutation yielded modest changes in interaction with ATP, possibly reflecting some long-range structural perturbation in this mutant. In glutamine-dependent ADP formation assays (Table II), we could not detect any activity with the native, wild type, or E261Q fCPSs, whereas K258L/E261Q did exhibit substantial ADP formation activity. The K258L/E261Q parameters were consistent with those determined in the glutaminase assay, with the Km for glutamine about equal to that of eCPS, and the kcat being somewhat lower. Although K258L displayed Michaelis-Menten behavior in the glutaminase assay and when ATP was the variable substrate in the glutamine-dependent ADP formation assay, it failed to do so when glutamine was the variable substrate in the latter assay (Table II). Instead, production of ADP by K258L was undetectable below a plateau glutamine concentration of ~1 mM, and, as glutamine concentration was incrementally increased to 20 mM, the rates measured did not show the expected correlation with substrate concentration (i.e. the apparent Vmax increased as the glutamine concentration ranged from 1 to 20 mM). This kinetic behavior suggested that the GAT domain of K258L was acting independently of the SYN domain and was not coupling glutamine cleavage to CP synthesis. The anomalous kinetic data further suggested that the K258L GAT domain, rather than channeling the ammonia sequestered within the protein, was releasing it into bulk solution so that CP could be formed only when the solution ammonia concentration was equivalent to that required for ammonia-dependent CP formation.

As an additional probe for synchronization between the GAT and SYN domains, we determined the relative rates of product formation for fCPSs (Fig. 3). When ammonia was the aminating substrate, the production of CP and ADP increased steadily with time of incubation and was consistently at or near the expected 1:2 ratio for wild type fCPS and all three of the mutants. With glutamine as the aminating substrate, the behavior of K258L and K258L/E261Q was markedly different, with the production of CP lagging behind production of glutamate in ratios as high as 1:13 and 1:10 for the double and single mutants, respectively. The ratio of CP/glutamate became larger with increasing time of incubation but remained far from the 1:1 ratio of a coupled system. Additionally, K258L and K258L/E261Q formed excess ADP relative to CP, with respective ratios of 6:1 and 8:1 early in the incubation and 3:1 ratios for both at 15 min. The uncoupling of ADP formation from CP formation most likely reflects the nonproductive turnover at the first ATP site that is known to occur when the intermediate carboxyl phosphate reacts with water rather than ammonia (1923). Together, these findings indicated that both K258L and K258L/E261Q failed to channel ammonia directly from the GAT to the SYN domain, thereby making CP formation dependent on sufficient buildup of the ammonia released into solution. The uncoupled character of K258L/E261Q was presumably masked in the assay for glutamine-dependent ADP formation, whereas that of K258L was apparent (Table II), because the double mutant has a relatively low Km for glutamine.



View larger version (26K):
[in this window]
[in a new window]
 
FIG. 3.
Relative rates of product formation in ammonia- and glutamine-dependent reactions catalyzed by K258L and K258L/E261Q. fCPSs, including K258L and K258L/E261Q, were incubated in a 1-ml volume for 5, 10, and 15 min at 37 °C, pH 7.6, in 50 mM HEPES, 50 mM NaHCO3, 10 mM ATP, 20 mM MgCl2, 10 mM KCl, 5 mM AGA, 1 mM dithiothreitol, 5 mM ornithine, and ornithine transcarbamoylase (0.2 units, Sigma). At the indicated times, 0.1-ml aliquots of the reaction mix were quenched and neutralized, and the amounts of CP (• and {circ}), ADP ({blacksquare} and {square}), and glutamate ({triangleup}) were determined as described previously (3).

 

Potential Roles for the GAT Domain—We conclude that the GAT domain must play a critical role in ammonia-specific fCPS, because it has been retained so faithfully that a single mutation, K258L, was sufficient to enable glutamine utilization. Occurrence of two simultaneous mutations (K258L/E261Q) was even more effective, whereas the E261Q mutation conferred no detectable gain of function, suggesting that the latter mutation provided compensatory structural stabilization to the Triad scaffolding. The GAT domain of present-day ammonia-specific CPSs might well serve an entirely structural role but might also contribute to the lower Km for ammonia relative to other amidotransferases. No ammonia site has yet been identified for any GAT, nor has it been determined whether there is an alternative to the tunnel for external ammonia entry to the SYN active site, possibly sharing access with ATP and bicarbonate (9, 20).

Our present findings clearly show that the cross-talk between the GAT and SYN domains that occurs in eCPS was not established in the fCPS mutants K258L and K258L/E261Q and that the ammonia derived from glutamine is not sequestered within the tunnel. It is not yet clear how extensive the underlying changes are (relative to a functional tunnel), whether they are confined to one or both domains, or what path is taken by ammonia between the GAT and SYN active sites. The molecular basis for coordination of the GAT and SYN active sites connected by a channel has been elucidated for two other GATs, glutamine phosphoribosylpyrophosphate amidotransferase (24, 25) and imidazole glycerol phosphate synthase (2628), and is based on a cycle of conformational changes that control access of substrates, intermediates, and bulk solvent to the active sites and/or the tunnel. Thus far, data for CPS are limited to a single solved conformation of eCPS and identification of 10 GAT residues that appear to line the interior of the tunnel (20). It is noteworthy that fCPS has retained seven of these ten residues and has conservative substitutions for the other three. Availability of a robust expression system for fCPS, the first reported for any ammonia-specific CPS, will greatly facilitate determination of the detailed molecular mechanism for present-day CPSs and should also further elucidate the evolution of both the CPS and GAT families.


    FOOTNOTES
 
* This work was supported by National Institutes of Health Grant DK54423. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed. Tel.: 617-373-2385; Fax: 617-373-3724; E-mail: spl{at}neu.edu.

1 The abbreviations used are: CPS, carbamoyl phosphate synthetase; AGA, N-acetylglutamate; CP, carbamoyl phosphate; fCPS, frog CPS; eCPS, E. coli CPS; GAT, glutamine amidotransferase; SYN, synthetase. Back


    ACKNOWLEDGMENTS
 
We thank Quinn Lu for the plasmid pESP-5 and Michael Kothe for a critical review of this manuscript.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Rubino, S. D., Nyunoya, H. & Lusty, C. J. (1986) J. Biol. Chem. 261, 11320–11327[Abstract/Free Full Text]
  2. Helbing, C. C. & Atkinson, B. G. (1994) J. Biol. Chem. 269, 11743–11750[Abstract/Free Full Text]
  3. Saeed-Kothe, A. & Powers-Lee, S. G. (2002) J. Biol. Chem. 277, 7231–7238[Abstract/Free Full Text]
  4. Mommsen, T. P. & Walsh, P. J. (1989) Science 243, 72–75[Medline] [Order article via Infotrieve]
  5. Randall, D. J., Wood, C. M., Perry, S. F., Bergman, H., Maloiy, G. M., Mommsen, T. P. & Wright, P. A. (1989) Nature 337, 165–166[CrossRef][Medline] [Order article via Infotrieve]
  6. Paulus, H. (1983) Curr. Top. Cell. Regul. 22, 177–200[Medline] [Order article via Infotrieve]
  7. Meister, A. (1989) Adv. Enzymol. Relat. Areas Mol. Biol. 62, 315–374[Medline] [Order article via Infotrieve]
  8. Thoden, J. B., Holden, H. M., Wesenberg, G., Raushel, F. M. & Rayment, I. (1997) Biochemistry 36, 6305–6316[CrossRef][Medline] [Order article via Infotrieve]
  9. Zalkin, H. & Smith, J. L. (1998) Adv. Enzymol. Relat. Areas Mol. Biol. 72, 87–144[Medline] [Order article via Infotrieve]
  10. Haraguchi, Y., Uchino, T., Takiguchi, M., Endo, F., Mori, M. & Matsuda, I. (1991) Gene 107, 335–340[Medline] [Order article via Infotrieve]
  11. Hosfield, T. & Lu, Q. (1999) BioTechniques 27, 58–60[Medline] [Order article via Infotrieve]
  12. Mori, M. & Cohen, P. P. (1978) J. Biol. Chem. 253, 8337–8339[Abstract]
  13. Powers-Lee, S. G. & Corina, K. (1986) J. Biol. Chem. 261, 15349–15352[Abstract/Free Full Text]
  14. Guadalajara, A., Grisolia, S. & Rubio, V. (1987) Eur. J. Biochem. 165, 163–169[Abstract]
  15. Evans, D. R. & Balon, M. A. (1988) Biochim. Biophys. Acta. 953, 185–196[Medline] [Order article via Infotrieve]
  16. Marshall, M. & Fahien, L. A. (1988) Arch. Biochem. Biophys. 262, 455–470[Medline] [Order article via Infotrieve]
  17. Anderson, P. M. & Meister, A. (1966) Biochemistry 5, 3157–3163[Medline] [Order article via Infotrieve]
  18. Cohen, N. S., Kyan, F. S., Kyan, S. S., Cheung, C. W. & Raijman, L. (1985) Biochem. J. 229, 205–211[Medline] [Order article via Infotrieve]
  19. Miles, B. W. & Raushel, F. M. (2000) Biochemistry 39, 5051–5056[CrossRef][Medline] [Order article via Infotrieve]
  20. Huang, X. & Raushel, F. M. (2000) Biochemistry 39, 3240–3247[CrossRef][Medline] [Order article via Infotrieve]
  21. Jones, M. E. & Lipmann, F. (1960) Proc. Natl. Acad. Sci. U. S. A. 46, 1194–1205
  22. Kothe, M., Eroglu, B., Mazza, H., Samudera, H. & Powers-Lee, S. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 12348–12353[Abstract/Free Full Text]
  23. Powers, S. G. & Meister, A. (1978) J. Biol. Chem. 253, 1258–1265[Medline] [Order article via Infotrieve]
  24. Krahn, J. M., Kim, J. H., Burns, M. R., Parry, R. J., Zalkin, H. & Smith, J. L. (1997) Biochemistry 36, 11061–11068[CrossRef][Medline] [Order article via Infotrieve]
  25. Chen, S., Burgner, J. W., Krahn, J. M., Smith, J. L. & Zalkin, H. (1999) Biochemistry 38, 11659–11669[CrossRef][Medline] [Order article via Infotrieve]
  26. Beismann, D. & Sterner, R. (2001) J. Biol. Chem. 276, 20387–20396[Abstract/Free Full Text]
  27. Korolev, S., Skarina, T., Evdokimova, E., Beasley, S., Edwards, A., Joachimiak, A. & Savchenko, A. (2002) Proteins 49, 420–422[CrossRef][Medline] [Order article via Infotrieve]
  28. Omi, R., Mizuguchi, H., Goto, M., Miyahara, I., Hayashi, H., Kagamiyama, H. & Hirotsu, K. (2002) J. Biochem. (Tokyo) 132, 759–765[Abstract]




This Article
Abstract
Full Text (PDF)
All Versions of this Article:
278/29/26722    most recent
M303774200v1
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Copyright Permissions
Google Scholar
Articles by Saeed-Kothe, A.
Articles by Powers-Lee, S. G.
Articles citing this Article
PubMed
PubMed Citation
Articles by Saeed-Kothe, A.
Articles by Powers-Lee, S. G.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.